Evidence map›Paper›PMID 25559604›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2015

Impact of age on retention in care and viral suppression.

Baligh R Yehia, Peter Rebeiro, Keri N Althoff, Allison L Agwu, Michael A Horberg, Hasina Samji, Sonia Napravnik, Kenneth Mayer, Ellen Tedaldi, Michael J Silverberg and 14 more

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Retention in HIV Care Still Matters: A Longitudinal Multisite Analysis.Journal of acquired immune deficiency syndromes (1999) · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Baligh R Yehia*Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; †Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN; ‡Department of Epidemiology, Johns Hopkins University, Baltimore, MD; §Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, Rockville, MD; ‖British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, Canada; ¶Department of Medicine, Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC; #The Fenway Institute, Boston, MA; **Department of Medicine, Temple University, Philadelphia, PA; ††Division of Research, Kaiser Permanente Northern California, Oakland, CA; ‡‡Ontario HIV Treatment Network, Toronto, ON, Canada; §§Retrovirus Research Center, Universidad Central del Caribe, Bayamon, PR; ‖‖Department of Medicine, University of Calgary, Calgary, AB, Canada; ¶¶Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL; ##Center for Comprehensive Access and Delivery Research and Evaluation, Iowa City Veterans Affairs Medical Center, Iowa City, IA; ***Montefiore Medical Center, Bronx, NY; and †††Department of Medicine, Divison of Allergy & Infectious Diseases, University of Washington, Seattle, WA.
Peter Rebeiro
Keri N Althoff
Allison L Agwu
Michael A Horberg
Hasina Samji
Sonia Napravnik
Kenneth Mayer
Ellen Tedaldi
Michael J Silverberg
Jennifer E Thorne
Ann N Burchell
Sean B Rourke
Anita Rachlis
Angel Mayor
Michael J Gill
Anne Zinski
Michael Ohl
Kathryn Anastos
Alison G Abraham
Mari M Kitahata
Richard D Moore
Kelly A Gebo
North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)

Funding

Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI OLAF KUTSCH · 1988 to 2026
$84.1M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
STATISTICAL AND DATA MANAGEMENT CENTERU01AI038855 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 1996 to 2006
$78.1M
Studies of Ocular Complications of AIDS - Coordinating CenterU10EY008057 · NEI · JOHNS HOPKINS UNIVERSITY · PI VAN NATTA, MARK L · 1988 to 2012
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
CIHR CBR-86906CIHR CBR-94036CIHR HCP-97105CIHR TGF-96118,Intramural NIH HHS Z01 CP010176NCATS NIH HHS UL1 TR000083NCATS NIH HHS UL1-TR000083NCI NIH HHS N02 CP055504NCI NIH HHS N02-CP55504NCI NIH HHS R01 CA165937NCI NIH HHS R01-CA165937NCI NIH HHS Z01-CP010214NCRR NIH HHS M01 RR000052NCRR NIH HHS MO1-RR-00052NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1-RR024131NEI NIH HHS K23 EY013707NEI NIH HHS U10 EY008052NEI NIH HHS U10 EY008057NEI NIH HHS U10 EY008067NEI NIH HHS U10-EY08052NEI NIH HHS U10-EY08057NEI NIH HHS U10-EY08067NIAAA NIH HHS R01 AA016893NIAAA NIH HHS R01-AA16893NIAAA NIH HHS U01 AA013566NIAAA NIH HHS U01-AA013566NIAAA NIH HHS U01 AA020790NIAAA NIH HHS U01-AA020790NIAAA NIH HHS U24 AA020794NIAAA NIH HHS U24-AA020794NIAID NIH HHS K01 AI071754NIAID NIH HHS K01-AI071754NIAID NIH HHS K01 AI093197NIAID NIH HHS K01-AI093197NIAID NIH HHS K24-AI065298NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI027763NIAID NIH HHS P30-AI027763NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI036219NIAID NIH HHS P30-AI036219NIAID NIH HHS P30 AI045008NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI054999NIAID NIH HHS P30 AI094189NIAID NIH HHS P30-AI094189NIAID NIH HHS P30-AI27757NIAID NIH HHS P30-AI27767NIAID NIH HHS P30-AI50410NIAID NIH HHS P30-AI54999NIAID NIH HHS R24 AI067039NIAID NIH HHS R24-AI067039NIAID NIH HHS R56 AI102622NIAID NIH HHS R56-AI102622NIAID NIH HHS U01 AI031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01 AI035039NIAID NIH HHS U01 AI035040NIAID NIH HHS U01 AI035041NIAID NIH HHS U01 AI035042NIAID NIH HHS U01 AI035043NIAID NIH HHS U01 AI037613NIAID NIH HHS U01 AI037984NIAID NIH HHS U01 AI038855NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI042590NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI069432NIAID NIH HHS U01 AI069434NIAID NIH HHS U01 AI069918NIAID NIH HHS U01-AI069918NIAID NIH HHS U01-AI31834NIAID NIH HHS U01-AI34989NIAID NIH HHS U01-AI34993NIAID NIH HHS U01-AI34994NIAID NIH HHS U01-AI35004NIAID NIH HHS U01-AI35039NIAID NIH HHS U01-AI35040NIAID NIH HHS U01-AI35041NIAID NIH HHS U01-AI35042NIAID NIH HHS U01-AI35043NIAID NIH HHS U01-AI37613NIAID NIH HHS U01-AI37984NIAID NIH HHS U01-AI38855NIAID NIH HHS U01-AI38858NIAID NIH HHS U01-AI42590NIAID NIH HHS U01-AI68634NIAID NIH HHS U01-AI68636NIAID NIH HHS U01-AI69432NIAID NIH HHS U01-AI69434NIAID NIH HHS UM1 AI035043NIAID NIH HHS UM1 AI068634NICHD NIH HHS U01 HD032632NICHD NIH HHS U01-HD32632NIDA NIH HHS F31 DA035713NIDA NIH HHS K24 DA000432NIDA NIH HHS K24-DA00432NIDA NIH HHS R01 DA004334NIDA NIH HHS R01 DA011602NIDA NIH HHS R01 DA012568NIDA NIH HHS R01-DA04334NIDA NIH HHS R01-DA11602NIDA NIH HHS R01-DA12568NIDA NIH HHS U01 DA036935NIDA NIH HHS U01-DA036935NIMHD NIH HHS G12 MD007583NIMHD NIH HHS G12-MD007583NIMHD NIH HHS U54 MD007587NIMH NIH HHS K23 MH097647NIMH NIH HHS K23-MH097647NIMH NIH HHS P30 MH062246NIMH NIH HHS P30-MH62246PHS HHS 90047713PHS HHS 90051652PHS HHS CDC200-2006-18797
6 · The paper itself

Abstract

backgroundRetention in care is important for all HIV-infected persons and is strongly associated with initiation of antiretroviral therapy and viral suppression. However, it is unclear how retention in care and age interact to affect viral suppression. We evaluated whether the association between retention and viral suppression differed by age at entry into care.

methodsCross-sectional analysis (2006-2010) involving 17,044 HIV-infected adults in 14 clinical cohorts across the United States and Canada. Patients contributed 1 year of data during their first full-calendar year of clinical observation. Poisson regression examined associations between retention measures [US National HIV/AIDS Strategy (NHAS), US Department of Health and Human Services (DHHS), 6-month gap, and 3-month visit constancy] and viral suppression (HIV RNA ≤200 copies/mL) by age group: 18-29 years, 30-39 years, 40-49 years, 50-59 years, and 60 years or older.

resultsOverall, 89% of patients were retained in care using the NHAS measure, 74% with the DHHS indicator, 85% did not have a 6-month gap, and 62% had visits in 3-4 quarters of the year; 54% achieved viral suppression. For each retention measure, the association with viral suppression was significant for only the younger age groups (18-29 and 30-39 years): 18-29 years [adjusted prevalence ratio (APR) = 1.33, 95% confidence interval (CI): 1.03 to 1.70]; 30-39 years (APR = 1.23, 95% CI: 1.01 to 1.49); 40-49 years (APR = 1.06, 95% CI: 0.90 to 1.22); 50-59 (APR = 0.92, 95% CI: 0.75 to 1.13); ≥60 years (APR = 0.99, 95% CI: 0.63 to 1.56) using the NHAS measure as a representative example.

conclusionsThese results have important implications for improving viral control among younger adults, emphasizing the crucial role retention in care plays in supporting viral suppression in this population.

Indexed as

Medication AdherenceViral LoadAdolescentAdultAgedAged, 80 and overAge FactorsCanadaCross-Sectional StudiesFemaleHIV InfectionsHumansMaleMiddle AgedUnited StatesYoung Adult

Identifiers

PMID25559604
PMCPMC4334738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.